Enantioseparation of binaphthol and its derivatives on cellulose tris(3,5-dimethylphenyl carbamate)

A Chiralcel OD-H column was used for the normal phase enantioseparation of binaphthol and its derivatives. Unexpectedly, binaphthol and its dibromo-substituted analogue could not be enantioseparated fully, whereas its ether and ester derivatives gave complete or partial resolution. Aspects of the chiral recognition are discussed further through calculated thermodynamic parameters

Solid substrate-room temperature phosphorimetry for the determination of trace lead using p-nitro-phenyl-fluorone-multi-wall carbon nanotubes-Tween-80 micellae compound and diagnosis about human diseases

The structures of multi-wall carbon nanotubes (MWNTs) were modified by H2SO4-HNO3 and H2SO4-H2O2, respectively. The corresponding products were water-soluble MWNTs-A and MWNTs-B. According to the experiment, it was found that MWNTs-B could emit stable solid substrate-room temperature phosphorescence (RTP) on the surface of paper with Ag+ as perturber. Under the conditions of 70 degrees C and 15 min, MWNTs-B can react with Tween-80 and P-nitro-phenyl-fluorone (R) to form R-MWNTs-B-Tween-80 micellae compound, which could emit RTP of R and MWNTs-B on the surface of paper, respectively. Pb2+ could cause the RTP of R and MWNTs-B enhanced sharply, respectively. Alp is directly proportional to the content of Pb2+. Anew solid substrate-room temperature phosphorimetry(SS-RTP) for the determination of trace Pb2+ has been established based on R-MWNTs-B-Tween-80 micellae compound containing double luminescent molecule. The detection limit of this method were 0.035 ag Pb2+ spot(-1) (8.8 x 10(-17) g Pb2+ ml(-1), MWNTs-B) and 0.028 ag Pb2+ spot(-1) (7.1 X 10(-17) g Pb2+ ml(-1), R). This method is of high sensitivity, good selectivity, high precision and accuracy. It could be applied to determine trace Pb2+ in serum samples at wavelength of 453.7/623.0 nm (R) or 475.9/645.0 nm (MWNTs-B) with satisfactory results, showing that SS-RTP has flexibility and utility value. Simultaneously, this method can be used to diagnose human diseases. The reaction mechanism for the determination of trace Pb2+ by SS-RTP based on R-MWNTs-B-Tween-80 micellae compound containing double luminescent molecule was also discussed. (C) 2008 Elsevier B.V. All rights reserved.Fujian Province Science Foundation [2006J0269, U0650025, 2006J0386]; Fujian Province education Committee [J1307143

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)

Abstract Background Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10–15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly diagnosed extensive-stage SCLC (ES-SCLC) is still platinum-based chemotherapy and as maintenance therapy scheme. Although most parts of patients experience a significant tumor response to first-line therapy, the disease recurs invariably. Anlotinib hydrochloride, a novel oral multitarget tyrosine kinase inhibitor, has significant inhibitory activity against angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR, and c-Kit kinase associated with tumor cell proliferation. Fluzoparib is a type of inhibitor of poly ADP ribose polymerase (PARP, including PARPl, PARP2 and PARP3). Previous studies have shown that Fluzoparib has a strong inhibitory effect on PARP1 activity at the molecular and cellular levels. Methods This is a multi-center, prospective, single-arm phase II clinical study. A total of 50 ES-SCLC patients who experienced disease progression after first-line standard platinum-based chemotherapy with/without immune checkpoint inhibitors scheme, or within 6 months after the completion of treatment will be recruited. Those who had prior treatment with any PARP inhibitor or antiangiogenic agent includes anlotinib, bevacizumab, sorafenib, and thalidomide are excluded. Eligible patients will receive oral anlotinib 8 mg once daily and oral fluzoparib 150 mg twice daily until disease progression or intolerable toxicity. The primary endpoint is objective response rate (ORR). Discussion The addition of fluzoparib to anlotinib is expected to increase the clinical benefit in ES-SCLC patients after platinum-based chemotherapy. Trial registration This study protocol was prospectively registered on June 17, 2021. ClinicalTrials.gov Identifier: NCT04933175

Preparation and characteristics of protein molecularly imprinted membranes on the surface of multiwalled carbon nanotubes

A novel protein molecularly imprinted membrane (PMIM) was synthesized on the surface of multiwalled carbon nanotubes (MWNTs) through a surface molecular imprinting technique by using bovine serum albumin (BSA) as the template molecule, acrylamide (AAm) as the functional monomer, N,N'-methylenebisacrylamide (NNMBA) as the cross-linker and ammonium persulphate [(NH4)(2)S2O8] as the initiator. The amounts of raw materials were optimized in this paper and the suitable amount is 0.1 g of CNTs, 0.02 g of BSA, 0.24 g of AAm, 0.1 g of MBA and 0.025 mg of (NH4)(2)S2O8. The selective recognition ability of PMIM/MWNTs was evaluated using adsorption experiments. Maximum adsorption capacity was 5.53 mu g/mg PMIM/MWNTs and a saturation value was achieved at a BSA concentration of 0.2 mg/mL The selectivity adsorption experiments showed that the PMIM/MWNTs also had higher adsorption capacities for BSA than for such molecules, as HSA, HB, pepsin and HRP. The PMIM/MWNTs displayed a 2.6-fold increase in affinity to BSA compared to the nPMIM/MWNTs. The PMIM/MWNTs, on the other hand, did not exhibit any significant change in affinity to other molecules compared to the nPMIM/MWNTs. In the experiment, the characteristics of the PMIM/MWNTs were analyzed using infrared spectroscopy and their configurations were observed using scanning electron microscopy. (c) 2009 Elsevier B.V. All rights reserved.Education Department, Fujian Province of China [JA07165]; National Nature Scientific Foundation of China (NSFC) [20775064

Biobjective Optimization Model Considering Risk and Profit for the Multienterprise Layout Design in Village-Level Industrial Parks in China

With the advent and development of Industry 4.0 and 5.0, manufacturing modes have changed and numerous newly complicated and integrated village-level industrial parks have emerged in the Southeast of China, where several enterprises are gathered in the same multistory building. The number of floors and surrounding enterprises can have an impact on accident risk. To reduce the overall risk level of industrial parks, the layout of enterprises with different risks needs to be well designed and optimized. However, to date, limited studies have been conducted to emphatically consider safety and optimize the enterprise layout at an industrial area level, and most studies focus on the cost of the layout. Therefore, this study proposed three biobjective mathematical optimization models to obtain the trade-off between minimizing risk and maximizing rental profit. Risk factors include the enterprise location and the association risk; the enterprise inherent safety risks are not considered. To solve this problem, a specific linearization strategy was proposed and an epsilon-constraint method was applied to obtain Pareto-optimal solutions. Subsequently, an industrial park in Shunde, China, was considered as a case study to verify the performance of the proposed models and methods. Finally, a sensitivity analysis of critical parameters was conducted. The critical factors influencing the objective functions were also analyzed to provide valuable managerial insights